Clinical Trial Update: REduced Frequency ImmuNE Checkpoint Inhibition in Cancers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on reduced-frequency immune checkpoint inhibition in cancers including renal cell carcinoma and melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Snippet

Sponsor: University College, London | Conditions: Renal Cell Carcinoma, Melanoma | Phase 2 | Status: UNKNOWN